Professor Nigel Temperton
Chair in Molecular Virology
Contact
Professor Nigel Temperton
Chair in Molecular Virology
01634 202957
Medway School of Pharmacy,
Anson Building,
Central Avenue,
Chatham Maritime,
Kent, ME4 4TB
United Kingdom
As Professor in molecular virology my R&D focus is on the design, development and deployment of viral pseudotype based neutralisation assays for influenza, coronavirus and other emerging viruses. This R&D has been funded by the MRC, the Bill & Melinda Gates Foundation, Innovate UK, the Wellcome Trust, the Rosetrees Trust and the Medway School of Pharmacy.
I am Director of the Viral Pseudotype Unit (VPU) within the University of Kent Medway School of Pharmacy, a purpose built, dedicated viral pseudotype R&D laboratory. The role of the VPU is to act as an interface between academia, industry, animal and public health laboratories with the purpose of translating basic virus research into in vitro cell culture based assays that can be readily employed for the efficacy testing of vaccines, antivirals and therapeutic antibodies.
I am a recognised global opinion leader in pseudotype virus platform technologies with 150+ peer-reviewed journal and review articles, and over 10,000 citations (h-index = 49). I am a consultant for VisMederi (Siena, Italy) and DIOSynVax (Cambridge, UK).
I am Director of the Viral Pseudotype Unit (VPU) within the University of Kent Medway School of Pharmacy, a purpose built, dedicated viral pseudotype R&D laboratory. The role of the VPU is to act as an interface between academia, industry, animal and public health laboratories with the purpose of translating basic virus research into in vitro cell culture based assays that can be readily employed for the efficacy testing of vaccines, antivirals and therapeutic antibodies.
I am a recognised global opinion leader in pseudotype virus platform technologies with 150+ peer-reviewed journal and review articles, and over 10,000 citations (h-index = 49). I am a consultant for VisMederi (Siena, Italy) and DIOSynVax (Cambridge, UK).
Projects
NIHR/HICC: Humoral Immune Correlates for COVID19
HICC: Humoral Immune Correlates for COVID19: Defining protective responses and critical readouts for Clinical Trials of Vaccines and Therapeutics
Rosetrees Trust and COVIDsortium
Antibody studies of Covid-19 (SARS-CoV-2): Protection, Pathogenesis and vaccine studies
Bill & Melinda Gates DIOS-UIVA
Digital Immune Optimized And Selected Universal Influenza Vaccine Antigens (DIOS-UIVA)
MRC COVID-19 Rapid Response Call
COVID-19: nCoV: Developing CoV-bnMABs for therapy of highly pathogenic coronaviruses including SARS-CoV-2
Wellcome Trust Epidemic Preparedness: COVID-19
A comprehensive study of immunopathogenesis of SARS-CoV-2 infection
Digital Immune Optimized and Selected Pan-Influenza Vaccine Antigens (DIOS-PIVa)
Publications
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2 directed antibody responses.
Aiste Dijokaite-Guraliuc, R. Das, D. Zhou, H. Ginn, Chang Liu, Helen M. E. Duyvesteyn, J. Huo, Rungtiwa Nutalai, P. Supasa, M. Selvaraj, T. D. de Silva, M. Plowright, T. A. Newman, H. Hornsby, A. Mentzer, D. Skelly, T. Ritter, Nigel James Temperton, P. Klenerman, E. Barnes, S. Dunachie, Cornelius Roemer, T. Peacock, N. Paterson, Mark A. Williams, David Hall, E. Fry, J. Mongkolsapaya, Jingshan Ren, David I. Stuart, G. Screaton
Cell Reports, 2023
Chinedu A. Ugwu, T. Olumade, E. Nwakpakpa, Venatius Onyia, E. Odeh, R. Duruiheoma, C. Ojide, Matthew Afam Eke, I. Nwafor, N. Chika-Igwenyi, Augustine M. Abu, B. Azuogu, N. Ajayi, E. Ogah, Oluwafemi Ayodeji, C. Abejegah, N. Adedosu, Nicholas E. Oyejide, S. Abah, Abiola Omidele, Winifred Ingbian, Emmanuel Osoba, P. Eromon, P. Oluniyi, Olusola A. Ogunsanya, A. Happi, P. Otuh, A. Nadesalingam, G. Carnell, N. Krause, Ernest T. Aguinam, R. Kinsley, D. Storisteanu, P. Tonks, D. Nelson, Carley E. McAlister, M. Boisen, R. Garry, E. Wright, Nigel James Temperton, S. Frost, J. Heeney, C. Happi
Scientific Reports, 2022
D. Cantoni, M. Mayora-Neto, A. Nadesalingam, D. Wells, G. Carnell, Luis Ohlendorf, Matteo Ferrari, P. Palmer, A. Chan, Peter Smith, E. Bentley, Sebastian Einhauser, R. Wagner, M. Page, G. Raddi, H. Baxendale, J. Castillo-Olivares, J. Heeney, Nigel J. Temperton
Frontiers in Immunology, 2022
A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
J. Huo, Aiste Dijokaite-Guraliuc, Chang Liu, R. Das, P. Supasa, M. Selvaraj, Rungtiwa Nutalai, D. Zhou, A. Mentzer, D. Skelly, T. Ritter, A. Amini, S. Bibi, S. Adele, Síle A. Johnson, N. Paterson, Mark A. Williams, D. Hall, M. Plowright, T. A. Newman, H. Hornsby, T. D. de Silva, Nigel James Temperton, P. Klenerman, E. Barnes, S. Dunachie, A. Pollard, T. Lambe, P. Goulder, E. Fry, J. Mongkolsapaya, Jingshan Ren, David I. Stuart, G. Screaton
Cell Reports, 2022
Kelly A. S. da Costa, J. M. D. Del Rosario, Matteo Ferrari, Sneha Vishwanath, B. Asbach, R. Kinsley, Ralf Wagner, J. Heeney, G. Carnell, Nigel James Temperton
Vaccines, 2022
View all
